MIT's Distributor in Malaysia Purchases MIT 1000 System

SAN CLEMENTE, CA--(Marketwire - October 21, 2009) - Micro Imaging Technology, Inc. (OTCBB: MMTC) announced that Biotek Sdn Bhd has purchased its first MIT 1000 System. MIT recently signed Biotek Sdn Bhd as its Distributor for Malaysia and other Association of Southeast Asian Nations (ASEAN) which includes Indonesia, Singapore, The Philippines, Thailand, Cambodia and others.

Biotek is a premier distributor in the food protection market and distributes products that are complementary to the MIT 1000 Rapid Microbial Identification System. "Our sales strategy is to demonstrate the features and benefits of this System in typical applications, enabling prospective clients to immediately understand its value. We have found this approach produces much faster sales than other traditional methods," stated Biotek's Director, W.C. Fong. Mr. Fong further stated, "We are pleased to add the MIT 1000 System to our product portfolio. Its rapid test time coupled with its low operating cost will be attractive to many of our customers."

Biotek will demonstrate the MIT 1000 System in December at the International Congress of Malaysian Society for Microbiology and will conduct various local hands-on workshops with the MIT 1000 System.

"Adding Biotek to our distribution network provides MIT with sales channels throughout the major countries in Asia. MIT already has distributors in China, Taiwan, South Korea, Japan, and Vietnam," stated John Ricardi, MIT's Executive Vice President. Mr. Ricardi further stated, "Our commercialization plan remains on track and we plan to add other key sales channels and a global contract manufacturer in the near term."

About Biotek Sdn Bhd:

Biotek is registered with the Registrar of Companies in Malaysia and with the Malaysian Ministry of Finance. It is fully owned by Focus Biotech Sdn Bhd which has numerous customers in the research, government and commercial sectors. The company's main focus is in sales, marketing and distribution of research and scientific products for the ASEAN countries (namely Malaysia, Singapore, Thailand, Brunei, Indonesia, Philippines, Vietnam, Cambodia, Laos and Myanmar). It is determined to be one of the best biotechnology companies serving the ASEAN countries. Biotek Sdn Bhd has facilities in Malaysia and Singapore that include demonstration, training and application laboratories for life sciences, biotechnology and clinical diagnostic applications.

More information on Biotek Sdn Bhd can be found at www.focusbiotech.com.my

About Micro Imaging Technology:

MIT is a California-based public company that has developed and patented a rapid microbial identification (ID) System that revolutionizes the pathogenic bacteria ID process and can annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process is totally GREEN requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3 billion -- having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues. www.micro-imaging.com

MIT recently completed an extensive, almost one-year in duration, evaluation by the AOAC Research Institute which included independent rigorous testing and thorough reviews by the AOAC RI and its expert reviewers, including the U.S. Department of Agriculture. The AOAC RI Report is available from the Company. www.aoac.org

Further, MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT recently performed over 300 tests for the identification of the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report is available from the Company and, in MIT's opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

Contact Information: CONTACT: Michael Brennan Chairman Email: Telephone: (805) 557-0614